ChiCTR2600116695 版本V1.0 版本创建时间2026/01/14 08:49:10 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600116695 

最近更新日期:

Date of Last Refreshed on:

2026-01-14 08:48:40 

注册时间:

Date of Registration:

2026-01-14 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

低强度脉冲聚焦超声促进产后子宫收缩安全性及有效性的多中心随机对照研究

Public title:

A Multicenter Randomized Controlled Trial Evaluating the Safety and Efficacy of Low-Intensity Pulsed Focused Ultrasound for Promoting Postpartum Uterine Involution

注册题目简写:

English Acronym:

研究课题的正式科学名称:

低强度脉冲聚焦超声促进产后子宫收缩安全性及有效性的多中心随机对照研究

Scientific title:

A Multicenter Randomized Controlled Trial Evaluating the Safety and Efficacy of Low-Intensity Pulsed Focused Ultrasound for Promoting Postpartum Uterine Involution

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘洪莉 

研究负责人:

罗欣 

Applicant:

Liu Hongli 

Study leader:

Xin Luo 

申请注册联系人电话:

Applicant telephone:

+86 183 7581 1064

研究负责人电话:

Study leader's telephone:

+86 158 2610 9160

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1054661042@qq.com

研究负责人电子邮件:

Study leader's E-mail:

14802315@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区袁家岗友谊路1号

研究负责人通讯地址:

重庆市渝中区袁家岗友谊路1号

Applicant address:

No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

Study leader's address:

No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

400016

研究负责人邮政编码:

Study leader's postcode:

400016

申请人所在单位:

重庆医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ZZ2021-664; 2025年科研伦审(ZZ2021-664-02)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

The Ethics Committee of the First Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2022-01-07 00:00:00

伦理委员会联系人:

严青

Contact Name of the ethic committee:

Yan Qing

伦理委员会联系地址:

重庆市渝中区袁家岗友谊路1号

Contact Address of the ethic committee:

No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 8901 1876

伦理委员会联系人邮箱:

Contact email of the ethic committee:

cyyy_ll@163.com

研究实施负责(组长)单位:

重庆医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区袁家岗友谊路1号

Primary sponsor's address:

No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院

具体地址:

重庆市渝中区袁家岗友谊路1号

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing

经费或物资来源:

超声医学工程国家重点实验室开放课题(2021KFKT013)

Source(s) of funding:

State Key Laboratory of Ultrasound in Medicine and Engineering(2021KFKT013)

Target disease:

Postpartum uterine involution

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.主要目的:深入研究LIPUS发挥作用的有效性和安全性; 2.次要目的:评估LIPUS对产后子宫复旧具体指标(子宫体积缩小速率、宫底高度下降速度及恶露持续时间)的影响。  

Objectives of Study:

1.The primary objective: To conduct an in-depth study on the effectiveness and safety of LIPUS in exerting its function; 2.The secondary objective: To evaluate the impact of LIPUS on specific indicators of postpartum uterine involution (the rate of uterine volume reduction, the speed of descent in the height of the uterine fundus, and the duration of lochia).

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

孕周≥37周、无严重产前并发症、愿意遵循规定的母乳喂养与产后锻炼计划、且计划进行阴道分娩的孕妇。

Inclusion criteria

Pregnant women with a gestational age of 37 weeks or more, without severe prenatal complications, willing to follow the prescribed breastfeeding and postpartum exercise plans, and planning to have a vaginal delivery.

排除标准:

前置胎盘、妊娠期肝内胆汁淤积症、多胎妊娠、巨大儿、羊水过多、有胎盘早剥病史或证据、重度子痫前期以及计划进行剖宫产的孕妇。

Exclusion criteria:

Placenta previa, intrahepatic cholestasis of pregnancy, multiple pregnancies, macrosomia, polyhydramnios, a history or evidence of placental abruption, severe preeclampsia, and pregnant women who plan to undergo cesarean section.

研究实施时间:

Study execute time:

From 2022-01-01 00:00:00 To 2026-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-08 00:00:00 To 2026-01-31 00:00:00  

干预措施:

Interventions:

组别:

低强度脉冲聚焦超声组

样本量:

553

Group:

Low-Intensity Pulsed Focused Ultrasound (LIPUS)

Sample size:

干预措施:

LIPUS 组接受了使用 Model-CKC100 型超声治疗设备进行的子宫复旧的疗法

干预措施代码:

Intervention:

The LIPUS group underwent therapy with a Model-CKC100 Ultrasound Therapeutic Device for Utero Involution

Intervention code:

组别:

对照组

样本量:

553

Group:

Control group

Sample size:

干预措施:

对照组进行子宫复旧安慰治疗,对产妇采用LIPUS治疗组相同仪器,操作方式亦相同,但 是全程不开启能量输出

干预措施代码:

Intervention:

The control group received uterine involution supportive treatment. For the parturients, the same equipment was used and the operation method was the same as that of the treatment group. However, the energy output was not activated throughout the process.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆医科大学附属妇女儿童医院 

单位级别:

三甲 

Institution
hospital:

Chongqing Medical University Affiliated Women and Children's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆医科大学附属大学城医院 

单位级别:

三甲 

Institution
hospital:

Chongqing Medical University Affiliated University Town Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

子宫体积缩小率

指标类型:

主要指标

Outcome:

Uterine volume reduction rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产褥感染

指标类型:

次要指标

Outcome:

puerperal infection

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

宫底高度

指标类型:

主要指标

Outcome:

fundal height

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子宫大小(超声测量二维指标)

指标类型:

附加指标

Outcome:

uterine dimensions (measured by ultrasound, including two-dimensional indicators and three-dimensional volume)

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

恶露持续时间

指标类型:

次要指标

Outcome:

duration of lochia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

对研究者和参试者设盲

Blinding:

Blinding of researchers and participants

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

平台网址:http://www.medresman.org.cn/ 公开时间:研究报告发表后半年内

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Platform website: http://www.medresman.org.cn/ Public period: Within six months after the publication of the research report

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有数据采集和管理由两部分组成,专门的超声治疗仪治疗产后子宫复旧后,由的不同工作人员记录病例数据,二是通过另外的工作人员将病例及产后测量的各项指标录入电子和管理系统。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All data collection and management consist of two components: first, specialized ultrasound therapy equipment is used to treat postpartum uterine involution, after which different staff members record data; second, the case information and various postpartum measurement indicators are entered into the electronic management system by separate staff.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-01-14 08:48:40